CYANOTECH CORP mit sehr guten Aussichten - 500 Beiträge pro Seite

[hautetom]

Hey,

Dieser Wert hat sehr großes Potentzial wenn die nächste Bilanz auch Positiven ausfällt.

Sollte man gut beobachten, bei Kursen um 1 Dollar kann man einsteigen.

Gruß Haute

[hautetom]

31.10.03 Cyanotech legen im 2.Quartal 04 beim Umsatz kräftig auf 2,84Mio. USD zu. Vor allem der Verkauf von Astaxanthin-Produkten in Japan und der steigende Absatz von BioAstin trugen zu diesem Wachstum bei. Der Nettoverlust wurde auf nur 10.000USD (0,00/Aktie) gesenkt. Gleichzeitig erhöhte sich das Barvermögen des Unternehmens auf 1,19Mio. USD.

[hautetom]

Kennt keiner diesen Wert ??

[js200]

Suche nach `cyanotech` (Stichwort)


Alle Threadtitel (Seitenansicht) Postings Ansicht Autor Letzte Antwort
CYANOTECH CORP mit sehr guten Aussichten 3 hautetom 31.12.03 12:23:52
Cyanotech - Das große Comeback !? 4 ustrading 07.11.03 16:07:58
Cyanotech wer hat welche? was geht abß 1 strandmann 07.01.01 13:59:32
Cyanotech ... 1 naughty by nature 18.08.00 16:30:37
Cyanotech, heute +70% 4 Matzeli 05.06.00 19:24:04


Nicht viele kennen CYAN, leider

JS200

[fonx]

Hatte ich schon mal vorgestellt,ist sehr schön gelaufen,FONX

[FUNDAMENTAL7]

Ich bin auch ein Aktinär von Cyanotech. Ih hatte den Wert

zufällig im Internet angetroffen. Nach einer kleiner

Analyse habe ich mir leider nur einen ganz kleinen Anteil

für 50 cent gekauft.Ich hoffe und glaube dass der nächste

Quartal mit einem Gewinn kommen wird. Zwar ein kleiner

Gewinn aber immerhin. Die Verkafserlöse steigen von

Quartal zu Quartal. Die Produkte lassen sich so gut

verkaufen wie seit langem nicht. Am wichtigten , es wird

kein Geld verbrannt. Also ein positer Cash flow.

Mein Kursziel lautet , in den kommenden 12 Monaten 4$



Grüsse von

Fundamental7

[hautetom]

Haben in den letzten Tagen gut zulegen können, bin gespannt wie es heute wird ?

[hautetom]

Warten bis der Kurs auf ca. 1,40 fällt und dann zugreifen und warten.
Kursziel: 3,0 € innerhlab 9 Monaten

[hautetom]

Leutet die Aktie kommt bald an die 1 US Dollar Grenze.
Für mich ist das wieder ein Kaufkurs, wartet noch eine oder zwei Wochen dann kaufen.

[hautetom]

News Release


<< Back


Cyanotech Corporation Reports Third Quarter Fiscal 2004 Financial Results; Company Reports Net Income of $109,000 on Increased Sales and Improved Gross Margin
KAILUA KONA, Hawaii--(BUSINESS WIRE)--Feb. 2, 2004--Cyanotech Corporation (Nasdaq:CYAN), a world leader in producing high-value natural products from microalgae, today announced financial results for the third quarter of its fiscal year 2004, ended December 31, 2003.

For the third quarter of fiscal 2004 the Company reported net income of $109,000, or $0.01 per diluted share, on sales of $3,024,000, compared to a net loss of $180,000, or ($0.01) per diluted share, for the comparable prior year period. The net sales for the quarter ended December 31, 2003 represent an increase of 6% from $2,840,000 recorded for the prior quarter and a year-over-year increase of 22% from $2,474,000 recorded for the comparable prior year period.

The Company achieved a gross profit margin of 39% for the quarter ended December 31, 2003, up from 30% in the prior quarter and 29% for the comparable prior year period. The improvement in gross profit margin from the prior quarter resulted from the effects of improvements in the Company`s cultivation processes, with the year-over-year improvement due primarily to increased bulk sales of higher margin natural astaxanthin products, NatuRose(R) and BioAstin(R). During the third quarter, operating expenses remained at 29% of sales, increasing by $63,000 from the expense level reported for the prior quarter. Improved gross profits, higher sales and a consistent level of operating expenses resulted in operating income of $292,000 for the third quarter of fiscal 2004, up from $32,000 in the prior quarter and contrasting with the loss from operations of $115,000 recorded for the comparable prior year period.

Net sales for the first nine months of fiscal 2004 were $8,292,000, an increase of 27% from $6,524,000 recorded for the comparable prior year period. The growth in revenues resulted from increased bulk sales of the Company`s natural astaxanthin products. For the first nine months of fiscal 2004, the Company reported a net loss of $42,000, or ($0.00) per diluted share, compared to the net loss of $1,505,000, or ($0.09) per diluted share, reported for the comparable period of the prior fiscal year.

The Company enters the final quarter of fiscal 2004 with working capital of $3,141,000 and a cash and cash equivalent balance of $1,517,000. This is in contrast to working capital of $2,352,000, and a cash and cash equivalent balance of $579,000 reported at the beginning of the current fiscal year. Furthermore, the voluntary conversion of a $1,250,000 convertible debenture to common stock in December 2003 has reduced long-term liabilities and increased net equity.

"We are extremely pleased by our return to profitability this quarter," said Gerald R. Cysewski, Ph.D., Chairman, President and Chief Executive Officer. "Our focus on all-around improvement in our operations has been validated by demonstrating sequential growth in sales, improved gross profit margins, increasing cash balances and profitability. These achievements are the result of hard work and determination of every employee of the Company." Dr. Cysewski added, "We are committed and determined to continue our efforts in sustaining profitability and growth in future periods."

About Cyanotech

Cyanotech Corporation, a world leader in microalgal technology, produces high-value natural products from microalgae and is the world`s largest commercial producer of natural astaxanthin (pronounced "asta-zan-thin") from microalgae. Products include BioAstin(R) natural astaxanthin, a powerful antioxidant with expanding applications as a human nutraceutical; NatuRose(R) natural astaxanthin for the aquaculture and animal feed industries; Spirulina Pacifica(R), a nutrient-rich dietary supplement; and phycobiliproteins, which are fluorescent pigments used in the immunological diagnostics market. Spirulina Pacifica and BioAstin are sold directly online through the Company`s website, www.nutrex-hawaii.com, as well as through resellers in over 30 countries worldwide. Technical information for the Company`s phycobiliproteins products is available at www.phycobiliprotein.com. Corporate data and other product information are available at www.cyanotech.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, forecasts of sales in future periods, changes in sales levels to our largest customers, weather patterns, risks associated with the acceptance of new products, competition, foreign exchange fluctuations, government regulation, and other factors more fully detailed in the Company`s recent Form 10-Q and annual form 10-K filings with the Securities and Exchange Commission.

Webcast

Cyanotech Corporation will hold a conference call on Monday, February 2, 2004 at 5:30 p.m. Eastern Time to be broadcast live over the Internet. It can be accessed by all interested parties by linking through the Investor Broadcast Network`s VCall website at www.vcall.com or through Cyanotech`s website, http://www.cyanotech.com. To access the simultaneous webcast on the Cyanotech site, select the Recent News section from Cyanotech`s home page. Click on the announcement entitled, "Cyanotech Announces Financial Results Webcast February 2, 2004." To listen to the live call, please go to either website at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. For those who are not able to listen to the live broadcast, a replay will be available shortly after the call and will be archived for a period of one calendar year.

CYANOTECH CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

Three Months Ended Nine Months Ended
December 30, December 30,
------------------ -----------------
2003 2002 2003 2002
--------- -------- -------- --------

NET SALES $ 3,024 $ 2,474 $ 8,292 $ 6,524
COST OF PRODUCT SALES 1,840 1,763 5,543 4,460
--------- -------- -------- --------
Gross profit 1,184 711 2,749 2,064
--------- -------- -------- --------

OPERATING EXPENSES:
Research and development 53 38 117 184
Sales and marketing 298 354 961 1,377
General and administrative 541 434 1,397 1,491
--------- -------- -------- --------
Total operating expenses 892 826 2,475 3,052
--------- -------- -------- --------

Income (loss) from operations 292 (115) 274 (988)
--------- -------- -------- --------

OTHER INCOME (EXPENSE):
Interest income 1 6 13 23
Interest expense (84) (92) (250) (339)
Other income (expense), net 14 21 17 (201)
--------- -------- -------- --------
Total other expense (69) (65) (220) (517)
--------- -------- -------- --------

Income (loss) before income
taxes 223 (180) 54 (1,505)

INCOME TAX PROVISION 114 - 96 -
--------- -------- -------- --------
NET INCOME (LOSS) $ 109 $ (180) $ (42) $(1,505)
========= ======== ======== ========

NET INCOME (LOSS) PER SHARE
Basic $ 0.01 $ (0.01) $ (0.00) $ (0.09)
========= ======== ======== ========
Diluted $ 0.01 $ (0.01) $ (0.00) $ (0.09)
========= ======== ======== ========

SHARES USED IN CALCULATION OF NET
INCOME (LOSS) PER SHARE:
Basic 18,777 18,284 18,471 17,703
========= ======== ======== ========
Diluted 18,934 18,284 18,471 17,703
========= ======== ======== ========

COMPREHENSIVE INCOME (LOSS):
Net income (loss) $ 109 $ (180) $ (42) $(1,505)
Other comprehensive income 9 8 28 10
--------- -------- -------- --------
$ 118 $ (172) $ (14) $(1,495)
========= ======== ======== ========


CYANOTECH CORPORATION
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands except per share amounts)
(Unaudited)

December March
31, 31,
2003 2003
----------- ----------

ASSETS
Current assets:
Cash and cash equivalents $ 1,517 $ 579
Accounts receivable, net 1,862 1,839
Refundable income taxes 3 9
Inventories 1,449 1,400
Prepaid expenses 85 40
----------- ----------
Total current assets 4,916 3,867

Equipment and leasehold improvements, net 11,951 12,777
Other assets 618 838
----------- ----------
Total assets $ 17,485 $ 17,482
=========== ==========

LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Current maturities of long-term debt $ 323 $ 323
Accounts payable 880 803
Accrued expenses 572 389
----------- ----------
Total current liabilities 1,775 1,515

Long-term debt, excluding current maturities 2,200 3,694
----------- ----------
Total liabilities 3,975 5,209
----------- ----------

Stockholders` equity:
Common Stock of $0.005 par value,
shares authorized 25,000,000; shares
issued and outstanding 20,242,277
at December 31, 2003 and 18,316,701
at March 31, 2003 101 92
Additional paid-in capital 26,660 25,418
Accumulated other comprehensive income
(loss) -- foreign currency
translation adjustments 25 (3)
Accumulated deficit (13,276) (13,234)
----------- ----------
Total stockholders` equity 13,510 12,273
----------- ----------

Total liabilities and stockholders` equity $ 17,485 $ 17,482
=========== ==========


CONTACT: Cyanotech Corporation
Jeffrey H. Sakamoto, 808-326-1353
[e-mail]
or
Guerrant Associates
Laura Guerrant, 808-882-1467 (Investors and Media)
[e-mail]

SOURCE: Cyanotech Corporation

[hautetom]

Mal warten was die nächsten Zahlen aussagen. Bei Kursen um 1 US Dollar kaufe ich.

[Lemmingway]

hat jemand die fundamentalen Kennzahlen(Verschuldung Eigenkapital, Gewinne etc. ?)

Algen -so wie sie CYAN herstellt- haben langfristig grosses Potenzial in der Welternährungskette

[FUNDAMENTAL7]

Leute wo seid Ihr, seid ihr alle schon raus aus Cyanotech?
Wir sind erst am Anfang einer 1000% Raily. Also noch ist es die Zeit drinzubleiben.

[JackLev]

die Algen schwimmen wieder nach oben...ich glaub`s ja nich...seit fünf Jahren ein Dümpler, und jetzt gute Aussichten? Na, heute schon 1,78 $ in Amiland